Generate Biomedicines GENB Q3 2026: Revenue Misses by 46% as Partner Deals Wind Down

Generate Biomedicines reported Q3 2026 revenue of $4.22 million, falling 46% short of the $7.75 million consensus estimate. The shortfall traces directly to the near-completion of performance obligations under its research agreements with Amgen and Novartis, which had been the primary source of collaboration revenue. That revenue stream has now shrunk from $9.6 million a year ago to $4.2 million this quarter.

The bottom line was equally difficult. GAAP EPS came in at a loss of $0.68, missing the consensus estimate of negative $0.55 by roughly 25%. R&D expense climbed to $82.3 million from $62.2 million a year ago, driven largely by spending on the two global Phase 3 SOLAIRIA trials testing GB-0895, the company's anti-TSLP antibody candidate, in severe uncontrolled asthma.

On the cash side, Generate ended the quarter with $404.2 million in cash, cash equivalents, and marketable securities. A $30 million upfront payment from a new collaboration with Zealand Pharma arrived in October, adding to that base. Management says the combined capital is expected to fund operations into the first half of 2028, but was explicit that additional financing will be required beyond that point.

The Zealand partnership carries up to nearly $1.2 billion in total potential milestones, focused on obesity and metabolic diseases, and includes an option for a third program. The company is also working with Anthropic on applying agentic AI to select and validate CAR T antigen combinations, and recently dosed the first patient in a Phase 1 trial for GB-5267, an IL-18-armored CAR T therapy targeting platinum-resistant ovarian cancer. The pipeline is active, but the funding runway and the collapse of legacy collaboration revenue leave the near-term financial picture under pressure.